Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis

  • 2011-09-08
  • Digestive Diseases and Sciences 57(2)
    • M. Malaguarnera
    • M. Vacante
    • T. Antić
    • M. Giordano
    • G. Chisari
    • R. Acquaviva
    • S. Mastrojeni
    • G. Malaguarnera
    • A. Mistretta
    • G. Volti
    • F. Galvano

Abstract

Background: Increased exposure to intestinal bacterial products may contribute to the pathogenesis of non alcoholic steatohepatitis (NASH). Bifidobacteria are predominant bacterial species in the human gut microbiota and have been considered to exert a beneficial effect on human health by maintaining the equilibrium of the resident microbiota.

Aims: To evaluate the effects of Bifidobacterium longum with fructo-oligosaccharides (Fos) in the treatment of NASH.

Methods: A total of 66 patients were randomly and equally divided into two groups receiving Bifidobacterium longum with Fos and lifestyle modification (i.e., diet and exercise) versus lifestyle modification alone. The following variables were assessed at -4 (beginning of the dietary lead-in period), 0 (randomization), 6, 12, 18, and 24 weeks: aspartate transaminase (AST), alanine transaminase (ALT), bilirubin, albumin, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, fasting plasma glucose, insulin, C-peptide, C-reactive protein (CRP), tumor necrosis factor (TNF)-α, homeostasis model assessment of insulin resistance (HOMA-IR), and serum endotoxins. Liver biopsies were performed at entry and repeated after 24 weeks of treatment.

Results: At the end of study period, we observed that the Bifidobacterium longum with Fos and lifestyle modification group versus the lifestyle modification alone group showed significant differences in the AST -69.6 versus -45.9 IU/mL (P < 0.05), LDL cholesterol -0.84 versus -0.18 mmol/L (P < 0.001), CRP -2.9 versus -0.7 mg/L (P < 0.05), TNF-α -0.45 versus -0.12 ng/mL (P < 0.001), HOMA-IR -1.1 versus -0.6 (P < 0.001), serum endotoxin -45.2 versus -30.6 pg/mL (P < 0.001), steatosis (P < 0.05), and the NASH activity index (P < 0.05).

Conclusions: Bifidobacterium longum with Fos and lifestyle modification, when compared to lifestyle modification alone, significantly reduces TNF-α, CRP, serum AST levels, HOMA-IR, serum endotoxin, steatosis, and the NASH activity index.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium lactis/longumImproved Insulin SensitivityBeneficial
Large
Bifidobacterium lactis/longumReduced AST LevelsBeneficial
Moderate
Bifidobacterium lactis/longumReduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium lactis/longumReduced Liver FatBeneficial
Moderate
Bifidobacterium lactis/longumReduced NASH Activity IndexBeneficial
Moderate
Bifidobacterium lactis/longumReduced Serum LPS LevelsBeneficial
Large
Bifidobacterium lactis/longumReduced TNF-α LevelsBeneficial
Large
Bifidobacterium longum B1-05Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum B1-05Improved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum B1-05Reduced Aminotransferase LevelsBeneficial
Moderate
Bifidobacterium longum B1-05Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum B1-05Reduced Low-Density Lipoprotein LevelBeneficial
Large
Bifidobacterium longum B1-05Reduced NASH ActivityBeneficial
Moderate
Bifidobacterium longum B1-05Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum B1-05Reduced Tumor Necrosis Factor AlphaBeneficial
Large
Bifidobacterium longum BI-05Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum BI-05Improved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum BI-05Reduced AST LevelsBeneficial
Moderate
Bifidobacterium longum BI-05Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum BI-05Reduced NASH Activity IndexBeneficial
Moderate
Bifidobacterium longum BI-05Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum BI-05Reduced TNF-α LevelsBeneficial
Large
Bifidobacterium longum HA-135Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum HA-135Improved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum HA-135Reduced Aspartate Transaminase ActivityBeneficial
Moderate
Bifidobacterium longum HA-135Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum HA-135Reduced LDL CholesterolBeneficial
Large
Bifidobacterium longum HA-135Reduced NASH ActivityBeneficial
Moderate
Bifidobacterium longum HA-135Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum HA-135Reduced Tumor Necrosis Factor AlphaBeneficial
Large
Bifidobacterium longum KABP-042Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum KABP-042Reduced AST LevelsBeneficial
Moderate
Bifidobacterium longum KABP-042Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum KABP-042Reduced LDL CholesterolBeneficial
Large
Bifidobacterium longum KABP-042Reduced Liver FatBeneficial
Moderate
Bifidobacterium longum KABP-042Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum KABP-042Reduced Tumor Necrosis Factor AlphaBeneficial
Large
Bifidobacterium longum MAK34B12LImproved Insulin SensitivityBeneficial
Large
Bifidobacterium longum MAK34B12LImproved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced AST LevelsBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced LDL CholesterolBeneficial
Large
Bifidobacterium longum MAK34B12LReduced NASH ActivityBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Serum Endotoxin LevelsBeneficial
Large
Bifidobacterium longum MAK34B12LReduced TNF-α LevelsBeneficial
Large
Bifidobacterium longum MM-2Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum MM-2Improved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum MM-2Reduced AST LevelsBeneficial
Moderate
Bifidobacterium longum MM-2Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum MM-2Reduced LDL CholesterolBeneficial
Large
Bifidobacterium longum MM-2Reduced NASH Activity IndexBeneficial
Moderate
Bifidobacterium longum MM-2Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum MM-2Reduced TNF-α LevelsBeneficial
Large
Bifidobacterium longum Rosell-175Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum Rosell-175Improved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum Rosell-175Reduced Aspartate Transaminase ActivityBeneficial
Moderate
Bifidobacterium longum Rosell-175Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum Rosell-175Reduced Low-Density Lipoprotein LevelBeneficial
Large
Bifidobacterium longum Rosell-175Reduced NASH Activity IndexBeneficial
Moderate
Bifidobacterium longum Rosell-175Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum Rosell-175Reduced Tumor Necrosis Factor AlphaBeneficial
Large
Bifidobacterium longum SD-5588Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum SD-5588Reduced Aspartate Transaminase ActivityBeneficial
Moderate
Bifidobacterium longum SD-5588Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum SD-5588Reduced Hepatic SteatosisBeneficial
Moderate
Bifidobacterium longum SD-5588Reduced LDL CholesterolBeneficial
Large
Bifidobacterium longum SD-5588Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum SD-5588Reduced Tumor Necrosis Factor AlphaBeneficial
Large
Bifidobacterium longum SP54Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum SP54Reduced AST LevelsBeneficial
Moderate
Bifidobacterium longum SP54Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum SP54Reduced LDL CholesterolBeneficial
Large
Bifidobacterium longum SP54Reduced Liver FatBeneficial
Moderate
Bifidobacterium longum SP54Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum SP54Reduced TNF-α LevelsBeneficial
Large
Bifidobacterium longum UABI-14Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum UABI-14Improved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum UABI-14Reduced Aspartate Transaminase ActivityBeneficial
Moderate
Bifidobacterium longum UABI-14Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum UABI-14Reduced Low-Density Lipoprotein LevelBeneficial
Large
Bifidobacterium longum UABI-14Reduced NASH Activity IndexBeneficial
Moderate
Bifidobacterium longum UABI-14Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum UABI-14Reduced Tumor Necrosis Factor AlphaBeneficial
Large
Bifidobacterium longum UABl-14Improved Insulin SensitivityBeneficial
Large
Bifidobacterium longum UABl-14Improved Liver SteatosisBeneficial
Moderate
Bifidobacterium longum UABl-14Reduced Aminotransferase LevelsBeneficial
Moderate
Bifidobacterium longum UABl-14Reduced C-Reactive Protein LevelsBeneficial
Moderate
Bifidobacterium longum UABl-14Reduced Low-Density Lipoprotein LevelBeneficial
Large
Bifidobacterium longum UABl-14Reduced Serum LPS LevelsBeneficial
Large
Bifidobacterium longum UABl-14Reduced Tumor Necrosis Factor AlphaBeneficial
Large
Back to top